Hodgkin lymfoom (HL)

html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

Home Behandelprotocollen HL

Hodgkin lymfoom (HL)

Diagnostiek

Stadiëring volgens Ann Arbor

Risicoclassificatie

Behandeling

Respons criteria

Follow up

Studies

Richtlijnen en literatuur

Beheer en wijzigingenhistorie

Naar alle behandelprotocollen